Efficacy of Anti-Vascular Endothelial Growth Factor (VEGF) Therapy for Age-Related Macular Degeneration. [PDF]
CureusBidiwala S.
europepmc +1 more source
Chinese translation validation of the adherence barrier questionnaire (intravitreal anti-vascular endothelial growth factor therapy) in Taiwan. [PDF]
Kaohsiung J Med SciChi YC, Hsieh HM, Müller S, Sheu SJ.
europepmc +1 more source
RETRACTION: Efficacy of Anti-Vascular Endothelial Growth Factor and Mitomycin C on Wound Gealing After Trabeculectomy in Glaucoma Patients: A Meta-Analysis. [PDF]
Int Wound Jeuropepmc +1 more source
Related searches:
Anti-vascular endothelial growth factor for neovascular glaucoma
Cochrane Database of Systematic Reviews, 2023Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segment of the eye. Anti-vascular endothelial growth factor (anti-VEGF) medications are specific inhibitors of the primary mediators of neovascularization ...
Thanitsara, Rittiphairoj +2 more
openaire +2 more sources
Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy
Ophthalmic Surgery, Lasers and Imaging Retina, 2020BACKGROUND AND OBJECTIVE: The purpose of this article is to review the role of anti-vascular endothelial growth factor (VEGF) therapy in treating patients with radiation retinopathy (RR). PATIENTS AND METHODS: RR can be associated with a significant decrease in visual acuity (VA ...
Nadim, Rayess, Prithvi, Mruthyunjaya
openaire +2 more sources
Use of anti‐vascular endothelial growth factor in the management of pterygium
Acta Ophthalmologica, 2016AbstractThe rising success of anti‐vascular endothelial growth factor (VEGF) therapies in ocular disease has stimulated the use of such treatments in the surgical management of pterygium. We reviewed the literature to better understand the safety and efficacy of the adjunctive role of anti‐VEGF treatments for pterygium excision.
Renata Kiri Mak +7 more
openaire +4 more sources
Anti-vascular endothelial growth factor and retinopathy of prematurity
British Journal of Ophthalmology, 2008Retinopathy of prematurity1 (ROP) has been at the nexus of a progressive understanding of neovascularisation, in large part because of the mouse model of oxygen-induced retinopathy (OIR) developed by Lois Smith.2 This model has been very instructive, because it has crystallised the hypothesis that ROP in general is caused by a two-step or two-phase ...
openaire +2 more sources
Anti-vascular endothelial growth factor agents for diabetic maculopathy
British Journal of Ophthalmology, 2009The management of diabetic macular oedema is changing. The therapeutic armamentarium for diabetic macular oedema (DMO) includes a new group of drugs that inhibit vascular endothelial growth factor (VEGF). These anti-VEGF agents are already being used widely in DMO in clinical practice despite that several phase III trials on these drugs are still ...
A, Salam, J, DaCosta, S, Sivaprasad
openaire +2 more sources
Anti‐vascular endothelial growth factor for myopic choroidal neovascularization
Clinical & Experimental Ophthalmology, 2012AbstractMyopic choroidal neovascularization (CNV) is a vision‐threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle‐aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized‐controlled study in treatment of subfoveal myopic CNV.
Danny S, Ng +2 more
openaire +2 more sources
Medicare Spending on Anti–Vascular Endothelial Growth Factor Medications
Ophthalmology Retina, 2018To analyze Medicare Part B spending on anti-vascular endothelial growth factor (VEGF) medications.Observational cohort study using Medicare Part B claims data released by the Centers for Medicare and Medicaid Services.Medicare Part B beneficiaries and their providers.Data from 2011 through 2015 were used to analyze intravitreal injection claims for ...
openaire +2 more sources